GB2630719A - Certain N-(1-cynao-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa - Google Patents

Certain N-(1-cynao-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa Download PDF

Info

Publication number
GB2630719A
GB2630719A GB2412566.8A GB202412566A GB2630719A GB 2630719 A GB2630719 A GB 2630719A GB 202412566 A GB202412566 A GB 202412566A GB 2630719 A GB2630719 A GB 2630719A
Authority
GB
United Kingdom
Prior art keywords
administration period
subject
months
oxazepane
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB2412566.8A
Other languages
English (en)
Other versions
GB202412566D0 (en
Inventor
Teper Ariel
Maes Andrea
Vergara Marcela
RAMIREZ Christina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of GB202412566D0 publication Critical patent/GB202412566D0/en
Publication of GB2630719A publication Critical patent/GB2630719A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB2412566.8A 2022-02-16 2023-02-16 Certain N-(1-cynao-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa Pending GB2630719A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263310751P 2022-02-16 2022-02-16
PCT/US2023/062731 WO2023159120A1 (en) 2022-02-16 2023-02-16 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Publications (2)

Publication Number Publication Date
GB202412566D0 GB202412566D0 (en) 2024-10-09
GB2630719A true GB2630719A (en) 2024-12-04

Family

ID=87579133

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2412566.8A Pending GB2630719A (en) 2022-02-16 2023-02-16 Certain N-(1-cynao-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Country Status (11)

Country Link
US (1) US20250144116A1 (enExample)
EP (1) EP4479059A4 (enExample)
JP (1) JP2025508359A (enExample)
KR (1) KR20240148350A (enExample)
CN (1) CN118695864A (enExample)
AU (1) AU2023221393A1 (enExample)
CA (1) CA3244131A1 (enExample)
GB (1) GB2630719A (enExample)
IL (1) IL314769A (enExample)
MX (1) MX2024009995A (enExample)
WO (1) WO2023159120A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
PT3758708T (pt) 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200179398A1 (en) * 2016-07-29 2020-06-11 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
US20200390781A1 (en) * 2018-02-07 2020-12-17 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
US20210186931A1 (en) * 2019-04-17 2021-06-24 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
US20210238152A1 (en) * 2014-01-24 2021-08-05 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024026433A2 (en) * 2022-07-28 2024-02-01 Insmed Incorporated Novel dpp1 inhibitors and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210238152A1 (en) * 2014-01-24 2021-08-05 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
US20200179398A1 (en) * 2016-07-29 2020-06-11 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
US20200390781A1 (en) * 2018-02-07 2020-12-17 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
US20210186931A1 (en) * 2019-04-17 2021-06-24 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochemical Pharmacology,2021, Korkmaz et al,"Cathepsin C inhibition as a potential treatment strategy in cancer". *

Also Published As

Publication number Publication date
CA3244131A1 (en) 2023-08-24
EP4479059A4 (en) 2026-01-28
GB202412566D0 (en) 2024-10-09
WO2023159120A1 (en) 2023-08-24
AU2023221393A1 (en) 2024-08-15
KR20240148350A (ko) 2024-10-11
JP2025508359A (ja) 2025-03-26
MX2024009995A (es) 2024-08-22
US20250144116A1 (en) 2025-05-08
EP4479059A1 (en) 2024-12-25
IL314769A (en) 2024-10-01
CN118695864A (zh) 2024-09-24

Similar Documents

Publication Publication Date Title
Cho et al. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution
Gaynes et al. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review
Giuliano Nonsteroidal anti-inflammatory drugs in veterinary ophthalmology
Camras et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery
US5981586A (en) Methods for treating proliferative and inflammatory skin diseases
US20200171007A1 (en) Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
US20250049813A1 (en) Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
JP2021512904A5 (enExample)
AU2018354090A1 (en) Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
US20250144116A1 (en) Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
MXPA05009789A (es) Combinacion de un antagonista del receptor de aldosterona y un agente antidiabetico.
JPH08169821A (ja) 血管漏出症候群を処置するための方法
TW202339731A (zh) 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法
Krishna et al. Efficacy of oxytetracycline hydrocortisone-soaked gauze pack on postoperative sequelae in lower third molar surgery: a prospective study
Omote et al. Roxadustat-induced central hypothyroidism in renal anemia patients: Insights from antineutrophil cytoplasmic antibody-related vasculitis cases
JP5033381B2 (ja) 外用医薬組成物
US5886045A (en) Remedy for allergic diseases in the region of the nose
Zou et al. OP0299 GENAKUMAB REDUCES THE RISK OF ACUTE GOUT FLARES DURING INITIATION OF URATE-LOWERING THERAPY: A PHASE 2, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, ACTIVE-CONTROLLED CLINICAL TRIAL
Baraka et al. Office-based steroid injection in benign vocal fold lesions
Blöchl‐Daum et al. Effects of cisplatin on urinary thromboxane B2 excretion
HK40113428A (en) Therapeutic agent for respiratory disease
CN110604735B (zh) 一种治疗肝纤维化、硬皮病的化合物及其应用
TW202404944A (zh) 呼吸器官疾病治療劑
CN118369098A (zh) 用于治疗进行性纤维化间质性肺病的新颖治疗组合
AU2017219121A1 (en) Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists